Lamivudin/Zidovudin Beta (Zidovudine, Lamivudine)

Both drugs are nucleoside analogues that are converted inside cells to active triphosphate forms. These active metabolites compete with natural nucleosides for incorporation into the viral DNA chain by reverse transcriptase, causing premature termination of the DNA strand and blocking HIV replication.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and the overall antiretroviral regimen. Patients should follow the exact instructions provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. The drug may be used if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and this decision should be made by a qualified healthcare provider.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

This combination provides two nucleoside reverse transcriptase inhibitors in a single tablet, simplifying regimens compared with taking separate agents. It is often used as a backbone in combination with non‑nucleoside reverse transcriptase inhibitors or protease inhibitors, offering comparable efficacy to other NRTI backbones such as tenofovir/emtricitabine.

Store the tablets at or below 25 °C in their original packaging, protected from moisture and direct sunlight. Do not expose the product to excessive heat or humidity, and keep it out of reach of children.

The medication is taken orally, usually with food or a glass of water, as directed by the prescribing clinician. Swallow the tablet whole; do not crush, chew, or split it unless specifically instructed by a healthcare professional.

Serious adverse events can include lactic acidosis, severe hepatic steatosis, bone‑marrow suppression leading to pancytopenia, and hypersensitivity reactions such as rash or fever. Patients should seek immediate medical attention if they experience unexplained fatigue, abdominal pain, rapid breathing, or signs of infection.

Individuals with known hypersensitivity to zidovudine, lamivudine, or any excipients in the tablet should avoid this medication. It is also contraindicated in patients with severe bone‑marrow suppression or uncontrolled liver disease, unless a specialist determines that benefits outweigh the risks.